Nov, 2021

Alzheimer: Schweizer Firma plant Diagnose-Zentren

November 2, 2021

Der Therapie-Ansatz besteht aus elektronischen Hirn-Stimulations-Sitzungen, die über ein tragbares Headset angewendet werden...
July, 2021

Bottneuro passes 2nd stage of Venture Kick: CHF 40'000.-

July 8, 2021

Bottneuro was selected by the Venture Kick's jury of experts as one of the winners of the second stage of financial and entrepreneurial support. Their projects provide neuromodulation therapies for Alzheimer's disease, offer an efficient all-in-one solution for creating structured medical reports, and develop solutions with far greater flexibility in either stationary or mobile energy storage applications.
Highlighted in
March, 2021

Bottneuro passes 1nd stage of Venture Kick: CHF 10'000.-

March 23, 2021

Bottneuro, together with Aegis Rider, Arkaïya, Celerato, and voltWALL win Venture Kick's first stage of financial and entrepreneurial support. Their projects develop a cutting edge augmented reality based safety system for motorcycles; produce a pioneer probiotic ingredient that promotes protection against a range of diseases and optimizes metabolism; provide neuromodulation therapies for Alzheimer's disease; offer an efficient all-in-one solution for creating structured reports, consisting of a comprehensive and intuitive software; and offer solutions with far greater flexibility in either stationary or mobile energy storage applications.
Highlighted in
February, 2021

Spin-Offs to Watch 2021: Bottneuro on Forbes DACH

February 24, 2021

Spin-Offs To Watch 2021": Bottneuro AG selected as one of the 30 most promising spin-offs in the DACH region! Bottneuro entwickelt ­ultradünne Implantate für die elektrische ­Stimulation von Rückenmark und Gehirn, um die Belastung von Patienten mit Alzheimer und chronisch neuropathischen Schmerzen deutlich zu reduzieren. Das erst 2021 gegründete Unternehmen wird von Bekim Osmani, Alois C. Hopf und Tino Töpper geführt; seine Technik soll ab Mitte 2023 bereits bei ersten Pa­tienten eingesetzt werden.
Highlighted in
August, 2019

Gebert Rüf supports NENI project with CHF 300'000.-

August 1, 2019

Within the Gebert Rüf Pilot Project, we are validated different stimulation protocols for non-neuronal cells using an in-vitro approach with NENI electrodes. Once successful, electrical stimulation protocols derived from in-vitro experiments will be translated to non-invasive transcranial electrical stimulations. By this, AD patients will benefit much earlier from our results and since the approach is non-invasive, it will become more accessible to a broader range of patients.